GET DAILY SIGNALSWhy Is Maze Therapeutics (MAZE) Stock Down -6.93% Today?
Key Takeaways
- MAZE traded at $33.59 in the opening minutes of Friday's session, down 6.93% from the prior close of $36.09.
- No company-specific news release, SEC filing, data readout or analyst rating change has been identified for Friday's decline.
- The pullback is unfolding against a softer biotechnology tape, with small-cap biotech benchmarks lower while the broad S&P 500 edged higher.
- Shares had climbed roughly 64% from their Sept. 21 close of $22.39 to $36.73 on Nov. 11, leaving the stock vulnerable to profit-taking.
- Post-earnings positioning remains a background factor after the company's Nov. 9 third-quarter report, which showed a wider net loss and a 59.7% jump in research spending.
- News Significance Score: 14/100 - No verified catalyst and a decline only about two and a half times the stock's typical daily move.
- Traders will watch whether the stock holds above the $30–$32 area and how turnover develops as the session matures, ahead of HORIZON data in early 2027.
- Investors can review Price Targets, Earnings and Forecast pages for deeper detail on the company's consensus expectations and reporting history.
- For systematic, rules-based exposure to volatile names like this one, explore Tickeron's Trending AI Robots.
Opening Summary
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company based in South San Francisco that designs small-molecule precision medicines for genetically defined kidney and metabolic diseases. Its lead asset, MZE829, is an oral APOL1 inhibitor in the Phase 2 HORIZON trial for APOL1-mediated kidney disease, while MZE782 targets phenylketonuria and chronic kidney disease.
In the first minutes of Friday's session, the stock changed hands at $33.59, a decline of $2.50, or 6.93%, from Thursday's close of $36.09. The direction was unambiguously negative. No verified company-specific catalyst accounts for the move; the decline instead coincided with renewed weakness across small- and mid-cap biotechnology while major equity indices traded modestly higher.
No Verified Catalyst: A High-Beta Name Correcting After a Sharp Run
No verified news or fundamental catalyst found in company disclosures, regulatory filings, newswire coverage or analyst actions explains Friday's drop. The assessment most consistent with the data is a combination of profit-taking after an extended rally and thin early-session liquidity exaggerating the percentage move.
The stock had risen from a Sept. 21 close of $22.39 to $36.73 on Nov. 11 — a gain of about 64% in roughly seven weeks — after Vertex Pharmaceuticals' positive Phase 2b data for inaxaplin validated the APOL1 mechanism that underpins MZE829. Momentum of that scale typically invites sellers, particularly in a name with a market capitalization near $1.84 billion and short interest equal to roughly 12% of shares outstanding, a combination that can amplify intraday swings.
The move also arrived minutes after the opening bell, when order books are thinnest. Friday's decline is roughly 2.5 times the stock's typical daily move of 2.73%, and only three of the last 60 sessions produced an absolute change as large — evidence of a normal, if sharp, correction rather than a reassessment of the pipeline.
Lingering Post-Earnings Overhang
The Nov. 9 third-quarter report remains a background factor rather than Friday's trigger. Maze posted a net loss of about $48 million, or $0.79 per share, on research and development spending of $40.2 million, up 59.7% year over year. Cash, equivalents and marketable securities stood at $477 million, which management expects to fund operations into 2029.
That quarter also brought a modest price-target trim to $51 from $53 at JPMorgan, which kept an Overweight rating, and continued disclosure of insider sales under pre-arranged trading plans. None of these items was published Friday, and the shares rose in the two sessions immediately following the report, so they explain sentiment rather than the timing of the decline.
Market Context and Trading Activity
The move was decisively stock-specific in magnitude but directionally aligned with the sector. The SPDR S&P Biotech ETF (XBI) slipped about 0.9% and the iShares Biotechnology ETF fell roughly 0.7%, while the S&P 500 gained about 0.3% and the Russell 2000 was roughly flat. Vertex Pharmaceuticals (VRTX), the sector's APOL1 bellwether, was little changed, indicating no fresh read-through from the competitive landscape.
Volume comparisons were not yet meaningful, since the decline occurred within the first minutes of trading; the stock's average daily turnover is roughly 550,000 to 700,000 shares. Technically, the shares remain far above their 50-day moving average near $28 and well below the 52-week high of $53.65, leaving the $30–$32 zone — the early-November breakout area — as the nearest reference point for support.
News Significance Score
The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. This event lands at 14 out of 100.
No verified news was found for Friday, so the news component is negligible relative to the company's roughly $1.8 billion valuation. The price component is modest rather than extreme: the 6.93% decline is about 2.5 times the stock's average absolute daily move of 2.73%, and moves of comparable size occurred only three times in the last 60 sessions. Two weak components combine into a low score.
What Comes Next for MAZE
The dominant catalyst is the final HORIZON dataset for MZE829 across all three AMKD cohorts, expected in early 2027, followed by a pivotal trial planned for the first half of 2027 subject to regulatory feedback. Topline Phase 2 CIPheR data for MZE782 in phenylketonuria is also guided for 2027, with a Phase 2 CKD study slated to begin in the first half of next year.
Nearer term, management's scheduled investor-conference appearances this month may offer incremental color on enrollment, spending cadence and trial design. Consensus remains strongly positive, with a large majority of covering analysts rated buy and a 12-month average target well above the current price — a gap that will be tested if execution slips.
Key risks include the accelerating expense base, potential equity dilution to extend runway, rate sensitivity across clinical-stage biotech, and competitive read-across from Vertex's AMPLITUDE interim analysis in early 2027, which could reset expectations for the entire APOL1 class.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. For traders navigating volatile clinical-stage names, reviewing this curated selection is a practical first step toward identifying strategies that are currently working.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for MAZE turns positive, indicating new upward trend
MAZE saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator turned positive. In 31 of the 33 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
MAZE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MAZE crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +5.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in 92 of 104 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 66 of 80 cases where MAZE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
MAZE broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.191) is normal, around the industry mean (3.498). P/E Ratio (-14.012) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement